The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 04, 2023
Filed:
Dec. 04, 2019
Applicant:
Arch Oncology, Inc., St. Louis, MO (US);
Inventors:
Pamela T. Manning, Chesterfield, MO (US);
Robyn Puro, St. Louis, MO (US);
Juan C. Almagro, Cambridge, MA (US);
Robert W. Karr, Frontenac, MO (US);
Assignee:
Arch Oncology, Inc., Brisbane, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61P 9/00 (2006.01); A61P 19/02 (2006.01); A61P 25/28 (2006.01); A61P 17/06 (2006.01); A61P 1/00 (2006.01); A61P 37/02 (2006.01); A61P 5/38 (2006.01); A61P 21/04 (2006.01); A61P 7/06 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61P 1/00 (2018.01); A61P 3/10 (2018.01); A61P 5/38 (2018.01); A61P 7/06 (2018.01); A61P 9/00 (2018.01); A61P 9/10 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 21/04 (2018.01); A61P 25/28 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 37/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract
Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.